| BACHURIN S O, BOVINA E V, USTYUGOV A A. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends[J]. Medicinal Research Reviews, 2017, 37(5): 1186-1225. doi: 10.1002/med.21434 |
| MASTERS C L, BATEMAN R, BLENNOW K, et al. Alzheimer's Disease[J]. Nature Reviewrs Disease Primers, 2015(1): 15056. |
| HOLTZMAN D M, MORRIS J C, GOATE A M. Alzheimer's Disease: The Challenge of the Second Century[J]. Science Translational Medicine, 2011, 3(77): 77sr1. |
| MASSON P, XIE W H, FROMENT M T, et al. Interaction between the Peripheral Site Residues of Human Butyrylcholinesterase, D70 and Y332, in Binding and Hydrolysis of Substrates[J]. Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular Enzymology, 1999, 1433(1/2): 281-293. |
| 张宝月, 庞晓丛, 贾皓, 等. 基于全球上市药物数据的抗阿尔茨海默病重定位新药发现[J]. 药学学报, 2019, 54(7): 1214-1224. doi: 10.16438/j.0513-4870.2019-0165 |
| KOŠAK U, BRUS B, KNEZ D, et al. The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity[J]. Journal of Medicinal Chemistry, 2018, 61(1): 119-139. doi: 10.1021/acs.jmedchem.7b01086 |
| CHEUNG J, RUDOLPH M J, BURSHTEYN F, et al. Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands[J]. Journal of Medicinal Chemistry, 2012, 55(22): 10282-10286. doi: 10.1021/jm300871x |
| SASTRY G M, ADZHIGIREY M, DAY T, et al. Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments[J]. Journal of Computer-Aided Molecular Design, 2013, 27(3): 221-234. doi: 10.1007/s10822-013-9644-8 |
| FRIESNER R A, BANKS J L, MURPHY R B, et al. Glide: a New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy[J]. Journal of Medicinal Chemistry, 2004, 47(7): 1739-1749. doi: 10.1021/jm0306430 |
| DIXON S L, SMONDYREV A M, KNOLL E H, et al. PHASE: a New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening: 1. Methodology and Preliminary Results[J]. Journal of Computer-Aided Molecular Design, 2006, 20(10-11): 647-671. doi: 10.1007/s10822-006-9087-6 |
| DIXON S L, SMONDYREV A M, RAO S N. PHASE: a Novel Approach to Pharmacophore Modeling and 3D Database Searching[J]. Chemical Biology & Drug Design, 2006, 67(5): 370-372. |
| ZHOU Y, LU X, DU C X, et al. Novel BuChE-IDO1 Inhibitors from Sertaconazole: Virtual Screening, Chemical Optimization and Molecular Modeling Studies[J]. Bioorganic & Medicinal Chemistry Letters, 2021, 34: 127756. |
| STERLING T, IRWIN J J. ZINC 15-Ligand Discovery for Everyone[J]. Journal of Chemical Information and Modeling, 2015, 55(11): 2324-2337. doi: 10.1021/acs.jcim.5b00559 |
| FELDER C E, BOTTI S A, LIFSON S, et al. External and Internal Electrostatic Potentials of Cholinesterase Models[J]. Journal of Molecular Graphics and Modelling, 1997, 15(5): 318-327. doi: 10.1016/S1093-3263(98)00005-9 |
| NOLTE H J, ROSENBERRY T L, NEUMANN E. Effective Charge on Acetylcholinesterase Active Sites Determined from the Ionic Strength Dependence of Association Rate Constants with Cationic Ligands[J]. Biochemistry, 1980, 19(16): 3705-3711. doi: 10.1021/bi00557a011 |
| BRUS B, KOŠAK U, TURK S, et al. Discovery, Biological Evaluation, and Crystal Structure of a Novel Nanomolar Selective Butyrylcholinesterase Inhibitor[J]. Journal of Medicinal Chemistry, 2014, 57(19): 8167-8179. doi: 10.1021/jm501195e |
| KNEZ D, BRUS B, COQUELLE N, et al. Structure-Based Development of Nitroxoline Derivatives as Potential Multifunctional Anti-Alzheimer Agents[J]. Bioorganic & Medicinal Chemistry, 2015, 23(15): 4442-4452. |
| KOŠAK U, BRUS B, KNEZ D, et al. Development of an In-Vivo Active Reversible Butyrylcholinesterase Inhibitor[J]. Scientific Reports, 2016, 6: 39495. doi: 10.1038/srep39495 |
| MEDEN A, KNEZ D, JUKIĈ M, et al. Tryptophan-Derived Butyrylcholinesterase Inhibitors as Promising Leads Against Alzheimer's Disease[J]. Chemical Communications (Cambridge, England), 2019, 55(26): 3765-3768. doi: 10.1039/C9CC01330J |
| ROSSI M, FRESCHI M, DE CAMARGO NASCENTE L, et al. Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease[J]. Journal of Medicinal Chemistry, 2021, 64(8): 4972-4990. doi: 10.1021/acs.jmedchem.1c00048 |
| TOUBLET F X, LALUT J, HATAT B, et al. Pleiotropic Prodrugs: Design of a Dual Butyrylcholinesterase Inhibitor and 5-HT6 Receptor Antagonist with Therapeutic Interest in Alzheimer's Disease[J]. European Journal of Medicinal Chemistry, 2021, 210: 113059-113064. doi: 10.1016/j.ejmech.2020.113059 |